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 Abstract 
  Background/Aim:   Matrix metalloproteinases (MMPs) play pivotal roles in extracellular matrix 
turnover and are involved in chronic kidney disease. The renoprotective action of a synthetic 
MMP inhibitor, compound A, was investigated in chronic nephritis.   Methods:   Nephritis was in-
duced by a single injection of anti-Thy1.1 antibody to unilaterally nephrectomized rats. The ef-
fects of compound A on proteinuria, blood urea nitrogen, and matrix-related gene expressions 
were evaluated. Collagen accumulation, as assessed by periodic acid-Schiff staining and hy-
droxyproline content, was determined. The integrity of glomerular epithelial cells and glomer-
ular basement membrane was evaluated with desmin immunohistochemistry and electron mi-
croscopic detection of anionic charge sites, respectively.   Results:   Treatment with compound A 
notably attenuated proteinuria, ameliorated blood urea nitrogen, and prevented glomerulo-
sclerosis. Gene upregulation of collagen and transforming growth factor     1 in the cortex was 
prevented in the treated animals. Glomerular epithelial cell injury was milder, and glomerular 
basement membrane anionic sites were protected with the treatment.   Conclusion:   A novel 
MMP inhibitor, compound A, exerts protective effects in progressive glomerulonephritis. Com-
pound A ameliorates various aspects of renal injuries and may have therapeutic potential to-
ward kidney diseases.    Copyright © 2012 S. Karger AG, Basel 
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 Introduction 
  Matrix metalloproteinases (MMPs) are a large family of zinc-dependent proteolytic en-
zymes which degrade various kinds of extracellular matrix (ECM) components. Twenty-
eight members of the MMP family have been identified  [1] . They are classified into four sub-
groups including gelatinases, interstitial collagenases, stromelysins, and the membrane-type 
MMPs (MT-MMPs). MMPs and their inhibitors, i.e. tissue inhibitors of metalloproteinase, 
are presumed to be implicated in the progression of chronic kidney disease (CKD) by affect-
ing ECM metabolism   [2–5]  . However, the precise pathological roles of these proteins in 
chronic renal disorders are not fully elucidated   [1]  . Since the accumulation of ECM repre-
sents an important pathological feature in the development of glomerulosclerosis and tubu-
lointerstitial fibrosis, there is little doubt that an impairment of the balance of ECM turnover, 
such as a decrease in matrix degradation or an enhancement of matrix synthesis, contributes 
to the progression of CKD. In general, MMP activity may counteract accumulation of ECM, 
thereby prevent CKD progression. However, on the contrary, mounting evidence has sug-
gested that some MMPs may contribute to a worsening of kidney diseases   [6, 7]  .
    MMP-2 is a gelatinase enzyme and has activity of degrading type IV collagen, a major 
component of the basement membrane. Pro-MMP-2 is activated by MT1-MMP and plasmin 
  [8, 9]  . MMP-2 is suggested to play a role in tubular cell epithelial-mesenchymal transition 
(EMT), a process by which differentiated epithelial cells undergo a phenotypic conversion to 
matrix-producing fibroblasts and myofibroblasts, degrade the tubular basement membrane, 
and generate interstitial fibrosis   [10]  . Transgenic expression of MMP-2 in tubular epithelial 
cells (TECs) leads to structural changes of the tubular basement membrane and phenotypic 
changes of TECs, two of the processes implicated in EMT   [11]  . In a canine disease model, 
MMP-2 expression is upregulated and localized in the area of the splitting tubular mem-
brane, suggesting MMP-2 involvement in EMT   [12]  .
    MMP-2 may also be involved in glomerular injury. After injury, increased activity of 
MMP-2, which is secreted by mesangial cells (MCs) in glomeruli and leukocytes penetrating 
into the glomerular basement membrane (GBM), results in the degradation of the GBM  [13–
15]  . We have previously shown that upregulation of MMP-2 in glomeruli contributes to glo-
merular damage by altering the GBM component in nephritic rats   [16]  . Furthermore, in pa-
tients with CKD, increased MMP-2 expression in glomeruli and a significant correlation 
between circulating MMP-2 activity and serum creatinine concentration have been reported 
 [17,  18] .
    Transforming growth factor (TGF)-    1 is a multifunctional cytokine which regulates 
ECM metabolism and has been shown to play a pivotal role in the development of irreversible 
kidney disease  [19, 20] . The possible involvement of TGF-   in the progression process of CKD 
includes a decrease in MMP synthesis and an enhancement of tissue inhibitors of metallopro-
teinase production   [1, 21]  . Unlike expression of other MMPs, however, MMP-2 expression is 
stimulated by TGF-     in vitro   [22]  . The enzymatic activity of MMP-2 is increased during kid-
ney disease, suggesting its detrimental aspect to kidney disease   [3, 23]  . In rats with acute glo-
merulonephritis, treatment with BB-1101, a non-selective MMP inhibitor, ameliorates mas-
sive proteinuria   [24]  . However, it remains uncertain whether or not the blockade of the enzy-
matic activity of MMP-2 is beneficial in the treatment of chronic glomerulonephritis.
    Compound A is a newly synthesized carbonyl acid derivative with potent and selective 
inhibition against MMPs, especially MMP-2 and MMP-8. This compound exerts little inhi-
bition on MMP-1, MMP-3, or MT1-MMP, and is available for oral use. The present study 
focused on the evaluation of the renoprotective action of the MMP inhibitor compound A 
in chronic anti-Thy1.1 glomerulonephritic rats. Our findings demonstrate possible therapeu-
tic intervention using this MMP inhibitor for the treatment of progressive kidney injury.135
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  M e t h o d s  
  Animals and Antibody 
 Male Wistar/ST rats were obtained from Japan SLC, Inc. (Shizuoka, Japan). The animals 
were housed at 25    °    C, 40–60% humidity, and in a 12-hour light-dark cycle. They were given 
free access to standard chow and tap water. All animal experiments complied with the Prin-
ciples of the Animal Care and Use Committee of Shionogi. Anti-Thy1.1 monoclonal anti-
body E30 was obtained from ascites fluid of mice   [25]  .
  MMP  Inhibitor 
 IC 50   v al u e s  o f  MM P  i nh i b i ti o n  o f  c o m p o un d  A  [ ( 2 R ) - 2 - { 5 - [ 4 - ( e th y l - m e th y l am i n o ) -
phenyl]-thiophene-2-sulfonylamino}-3-methyl-butyric acid] ( fig. 1 a) were determined using 
purified human MMPs and quenched fluorescent peptide substrates   [26]  . A pharmacoki-
  Fig. 1.   Structure and concen-
tration-dependent inhibition of 
compound A, and plasma con-
centration-time profile in rats. 
  a   Chemical structure of com-
pound A.   b   Inhibitory dose-re-
sponse curves of compound A for 
MMP-1, -2, -3, -8, -9, and -13 and 
MT1-MMP.   c   The mean plasma 
concentrations of compound A at 
0, 0.5, 1, 2, 4, 6, and 24 h after oral 
administration were evaluated. 136
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netic study of compound A was performed. The drug suspended with 0.5% methylcellulose 
solution was orally administered to rats (n = 6) at a dosage of 3 mg/kg, and blood samples 
were taken at 0, 0.5, 1, 2, 4, 6, and 24 h. The blood concentrations of compound A were de-
termined by reverse-phase high-performance liquid chromatography. Pharmacokinetic pa-
rameters were calculated using WinNonLin software (Pharsight Inc.).
  Pharmacological  Study 
 Six-week-old Wistar/ST rats were used in this study. Under anesthesia with sodium pen-
tobarbital, the left kidney was removed through a flank incision. Two weeks after nephrec-
tomy, nephritis was induced by a single injection of E30 (70     g/rat) into the tail vein. The 
same volume of saline was administered to control rats. The rats were allocated into three 
groups: control group (n = 3), nephritis group (n = 7), and compound A treatment group 
(n = 7). Compound A was orally given at a dose of 3 mg/kg 1 h prior to E30 injection and 
consecutively administered once a day throughout the experiment. Each animal was kept in 
a metabolic cage to collect the 24-hour urine sample at the indicated time points. Plasma 
samples were collected from the tail vein.
    The rats were sacrificed at week 23. The kidney, liver, spleen, and adrenal were harvest-
ed and tissue weights were measured. For histological examination, part of the kidney was 
fixed in formalin and embedded in paraffin. Sections up to 4     m in thickness were stained 
with periodic acid-Schiff (PAS) and hematoxylin. For hydroxyproline measurement, renal 
cortical tissue was frozen with dry ice and kept at –80    °   C.
    Among the animals in each group, several rats (control group: n = 3, nephritis group: 
n = 4, compound A treatment group: n = 4) were used for gene expression analysis, electron 
microscope examination, and immunohistochemistry. The selection of rats was based on the 
average urinary protein excretion (UPE) at 23 weeks. For gene expression analysis, RNA was 
isolated from renal cortices and glomeruli. For electron microscope examination, polyethyl-
eneimine was injected via the tail vein at 15 min before sacrifice to detect anionic charge sites 
(ACSs) on the GBM. For immunohistochemistry, part of the kidney was fixed in formalin 
and embedded in paraffin to identify the expression of desmin.
  Miscellaneous  Measurements 
  Urinary protein was determined by the pyrogallol red method, and blood urea nitrogen 
(BUN) was determined by the urease indophenol method (Wako Chemical Industries Ltd., 
Osaka, Japan). Plasma total cholesterol, triglyceride, non-esterified fatty acids (NEFA), as-
partate transaminase (AST), and alanine transaminase (ALT) were measured by routine 
methods on a Hitachi-7070 clinical autoanalyzer.
  Morphological  Study 
  Glomerulosclerosis was evaluated with quantitative measurement of the PAS-stained 
area in glomeruli. For each section, 30 (control group) or 50 (nephritis and treatment groups) 
randomly selected glomeruli were subjected to computer image analysis (Raizu Co. Ltd., 
Sendai, Japan). The percentage of glomerular area with PAS staining was calculated as the 
index of glomerulosclerosis.
    Tubulointerstitial injury was defined as inflammatory cell infiltration, tubular dilation, 
and interstitial fibrosis. Injury was graded semiquantitatively on a scale of 0–4 as previously 
described  [27] . The average score of 10 fields was determined as the index of tubulointerstitial 
lesions.137
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    Determination of Hydroxyproline Content 
 The collagen content was assessed by determining total hydroxyproline according to the 
method of Kivirikko et al.   [28]  . The results were expressed as hydroxyproline per protein. 
Protein was determined according to the Lowry method.
    Quantitative Analysis of Gene Expression 
  Real-time polymerase chain reaction (PCR) was performed using the ABI PRISM 7000 
Sequence Detection System (Applied Biosystems, Foster City, Calif., USA). The primer pairs 
and probes were used for real-time PCR detection as previously reported   [16]  .
    Detection of ACSs on the GBM 
  The detection of ACSs on the GBM was performed as previously reported   [29]  . The kid-
ney was cut into small pieces and immersed in a mixture of 0.1% glutaraldehyde and 2% 
phosphotungstic acid. The samples were postfixed in 2% OsO  4   buffered with sodium caco-
dylate buffer. The tissue pieces were rinsed, dehydrated, and embedded in epoxy resin. Ul-
trathin sections were contrasted with lead citrate and examined with an electron microscope 
(100-CX; Jeol, Tokyo, Japan).
  Immunohistochemistry 
 Immunohistochemistry for desmin was carried out as previously reported  [27] . The sec-
tions were incubated with HRP-conjugated anti-human desmin (DAKO, Glostrup, Den-
mark) and incubated with diaminobenzidine solution. For each section, 10 glomeruli were 
assessed based on the degree of staining for desmin. Glomerular desmin was scored semi-
quantitatively in a blind fashion, according to a scale of 0–3.
  Statistical  Analysis 
  Values are expressed as the mean and standard error. Student’s t test was used. For all 
experiments, statistical significance was set at p   !   0.05.
  R e s u l t s  
 IC 50   Values and Pharmacokinetics of Compound A 
 The  IC 50   values (in n  M  ) of compound A for MMP inhibition were as follows: MMP-1 
  1  10,000, MMP-2 4.2, MMP-3 1,790, MMP-8 15.1, MMP-9 37.4, MMP-13 69.7, and MT1-
MMP (MMP-14) 1,580 (  fig. 1  b). Plasma concentrations after orally administered 3 mg/kg of 
compound A reached the maximal level of 2.9    M  at 0.5 h and gradually decreased to 0.4    M  
at 6 h and became undetectable at 24 h (  fig. 1  c). The mean area under the plasma concentra-
tion-versus-time curve (AUC 24 h) was 11     M  /h. The blood concentration of compound A 
indicated that an oral dosage of 3 mg/kg compound A was expected to inhibit MMP-2 activ-
ity.
    Effects of Compound A on UPE, BUN, and Morphological Changes 
  Effects of compound A on UPE and BUN in nephritic animals are shown in   figure 2  . 
UPE exhibited a biphasic increase (  fig. 2  a). The first increase was rapidly observed within 1 
week after antibody injection. After the peak, it showed a transient recovery from the second 
to the fourth week. UPE increased again from week 4 to the end of the study (23 weeks). BUN 
continuously increased from week 7 after the nephritis induction, accompanied by the in-
crease in UPE (  fig. 2  b). In control unilaterally nephrectomized rats, the amount of UPE and 
the level of BUN showed little change. Suppression of UPE in the compound A-treated rats 138
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was demonstrated from day 2 to week 23 (  fig. 2  a). Treatment with compound A significant-
ly decreased BUN values at weeks 13, 16, and 23 (  fig. 2  b).
    Representative morphological changes in kidney tissues of nephritic rats at the end of 
the study are shown in   figure 3  a–c. A marked accumulation of ECM in glomeruli of the ne-
phritis group was observed, showing typical glomerulosclerosis (  fig. 3  b). Tuft adhesion to 
Bowman’s capsule was frequently observed, suggesting glomerular epithelial cell (GEC) in-
jury. Tubular atrophy and infiltration of inflammatory cells into the interstitial area were 
detected in the nephritic group. On the other hand, treatment with compound A obviously 
attenuated these histological changes in the nephritic rats (  fig. 3  c). Measurement of PAS 
staining in the glomeruli was examined to evaluate glomerulosclerosis (  fig. 3  d). The PAS 
staining index in nephritic rats was significantly higher than that in control rats. Treatment 
with compound A significantly suppressed glomerulosclerosis. Semiquantitative analysis of 
kidney damage revealed that the scores of tubulointerstitial injuries were remarkably high in 
nephritic rats, and treatment with compound A reduced the scores, although not signifi-
cantly (  fig. 3  e). The amount of hydroxyproline in the renal cortex was determined to assess 
the effect of compound A on collagen contents in the kidney tissue (  fig. 3  f). Hydroxyproline 
contents in nephritic rats significantly increased compared with those in control rats. Treat-
ment with compound A significantly attenuated the increase in hydroxyproline in the ne-
phritic rats. These results corresponded to the findings from the morphological studies.
  Fig. 2.   Effect of compound A on 
UPE and BUN in nephritic rats. 
  a  Plots show the mean values and 
bars the standard errors. Open 
circles: unilaterally nephrecto-
mized control rats (n = 3); closed 
circles: nephritic rats (n = 7); 
gray circles: rats treated with 
compound A (n = 7).   b   Columns 
show the mean values and bars 
the standard errors. White col-
umns: unilaterally nephrecto-
mized control rats (n = 3); black 
columns: nephritic rats (n = 7); 
gray columns: rats treated with 
compound A (n = 7).   *  p   !   0.05: 
significantly different from the 
control group.   #  p   !   0.05: signifi-
cantly different from the nephri-
tis group. 139
Nephron Extra 2012;2:133–146
 DOI:  10.1159/000338801 
  Published online: May 26, 2012 
EXTRA
  Kuroda et al.: Renoprotective Action of a Matrix Metalloproteinase Inhibitor 
www.karger.com/nne
  © 2012 S. Karger AG, Basel 
  Fig. 3.   E ff e ct  o f  c o m p o un d  A  o n  gl o m e rul o s c l e r o s i s  an d  tu b ul o in t e r s ti ti al  in j ury  in  n e p h ri ti c  r a t s .  
  a–c   Light microscopy of kidney tissues stained with PAS.   a   Unilaterally nephrectomized control rat. 
  b   Nephritic rat. A single injection of E30 to unilaterally nephrectomized rats induced deposition of ECM 
in glomeruli and tubulointerstitial fibrosis.   c   Treatment with compound A. Drug treatment suppressed 
the morphological changes in both glomeruli and the tubulointerstitial area. Scale bar = 50    m. 
  d   PAS-stained area in glomeruli was measured using computer image analysis to evaluate glomeruloscle-
rosis.   e   Semiquantitative analysis of tubulointerstitial injury.   f   Hydroxyproline contents in renal cortices. 
  d–f   Columns show the mean values and bars the standard errors. White columns: unilaterally nephrec-
tomized control rats (n = 3); black columns: nephritic rats (n = 7); gray columns: rats treated with com-
pound A (n = 7).   *  p   !   0.05: significantly different from the control group.   #  p   !   0.05: significantly differ-
ent from the nephritis group. 140
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    Tissue weights of the kidney, liver, spleen, and adrenal were increased in nephritic rats, 
and treatment with compound A ameliorated hypertrophy of the kidney, liver, and spleen 
(  table 1  ). The elevated values of total cholesterol, triglyceride, and NEFA in nephritic rats 
were lower in the compound A-treated animals (  table 2  ). There were little changes in AST 
and ALT levels in the nephritic and compound A-treated rats (  table 2  ). These results suggest 
that compound A exhibited a renoprotective action without inducing hepatic injury.
    Effects of Compound A on Matrix-Related Gene Expressions 
  To further analyze the effect of compound A on ECM deposition, changes of gene ex-
pression of    1(I),     1(III), and     1(IV) collagen as well as of TGF-    1 were examined (  fig. 4  a–
d). The expressions of   1(I),   1(III),   1(IV), and TGF-  1 were apparently upregulated in the 
renal cortex of nephritic rats. Treatment with compound A significantly decreased the eleva-
tion of these gene expressions.
    We have previously demonstrated that a change in the expression of MMP-2 was in-
volved in the progress of chronic anti-Thy1.1 glomerulonephritis. Therefore, gene expression 
of MMP-2 in glomeruli was measured at the end of the study (  fig. 4  e). MMP-2 expression 
was increased in the nephritis group, as previously reported. Treatment with compound A 
suppressed the increase in MMP-2 gene expression.
Table 1. E  ffect of compound A on tissue weight in chronic Thy-1.1 nephritic rats
Kidney
g/kg BW
Liver
g/kg BW
Spleen
g/kg BW
Adrenal
g/kg BW
Control (n = 3) 5.3680.46 25.780.5 1.2980.01 0.09880.003
Nephritis (n = 7) 7.9080.64* 29.780.8* 1.6180.05* 0.11580.003*
Compound A (n = 7) 6.4780.49 27.080.8# 1.3580.06# 0.10980.005
T  issue samples from unilaterally nephrectomized rats (Control), nephritic rats (Nephritis), and rats 
treated with compound A (Compound A) were collected. Data represent the mean and standard error. 
BW = Body weight. * p < 0.05: significantly different from the control group. # p < 0.05: significantly dif-
ferent from the nephritis group.
Table 2. P  lasma lipid, AST, and ALT levels at the end of the study
TC
mg/dl
TG
mg/dl
NEFA
Eq/l
AST
U/l
ALT
U/l
Control (n = 3) 69.783.6 36.789.0 1,066834 91.382.2 63.887.1
Nephritis (n = 7) 181.9825.3* 104.0815.7* 1,5758223 87.487.8 69.984.0
Compound A (n = 7) 95.9818.3# 62.9815.1 1,2338109 91.483.2 66.883.6
P  lasma samples from unilaterally nephrectomized rats (Control), nephritic rats (Nephritis), and rats 
treated with compound A (Compound A) were collected. Data represent the mean and standard error. 
TC = Total cholesterol; TG = triglyceride. * p < 0.05: significantly different from the control group. # p < 
0.05: significantly different from the nephritis group.141
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    Effects of Compound A on Injury of the GBM and GECs 
  To further study GBM injury, the effect of compound A on the number of ACSs on the 
GBM was evaluated.   Figure 5   shows the typical electron micrograph of glomerular capillary 
walls after polyethyleneimine perfusion. In control rats, electron-dense deposits consisting 
of the heparan sulfate-polyethyleneimine complex were distributed as linear arrays along the 
GBM ( fig. 5 a). Foot processes of GECs were regularly distributed along the GBM. In nephrit-
  Fig. 4.   Effect of compound A on gene expressions in nephritic rats. Quantitative analysis of gene expres-
sions by real-time PCR for     1(I) collagen (  a ),     1(III) collagen (  b ),     1(IV) collagen (  c ),  TGF-  1  ( d ),  and 
MMP-2 (  e  ). Columns show the mean values and bars the standard errors. White columns: unilaterally 
nephrectomized control rats (n = 3); black columns: nephritic rats (n = 4); gray columns: rats treated with 
compound A (n = 4).   *  p   !   0.05: significantly different from the control group.   #  p   !   0.05: significantly 
different from the nephritic group. 142
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ic rats, the number of stained ACSs was prominently decreased, and the effacement of foot 
processes was widely observed (  fig. 5  b). On the other hand, treatment with compound A 
maintained the number of ACSs and alleviated abnormal fusion of foot processes on the 
GMB (  fig. 5  c).   Figure 5  d shows the protective effect of compound A on the number of ACSs 
in each group at the end of the study.
  To further analyze the action of compound A in GEC damage, immunostaining for des-
min was performed as a marker for GEC injury. Staining for desmin was rarely observed in 
the control glomeruli ( fig. 6 a). In nephritic rats, an apparent expression of desmin was noted, 
and the staining score was significantly high (  fig. 6  b, d). In contrast, the expression of glo-
merular desmin was clearly less intense and decreased in rats treated with compound A 
( fig. 6 c,  d).
  Fig. 5.   ACS analysis. Electron micrographs of the parts of glomerular capillary walls perfused with poly-
ethyleneimine at the end of the study.   a   Unilaterally nephrectomized control rat. ACSs on the GBM were 
distributed at a constant distance.   b   Nephritic rat. GECs are flat and their foot processes are effaced after 
the induction of nephritis. The number of ACSs on the GBM was reduced.   c   Rat treated with compound 
A. Drug treatment improved the alteration of cell form of GECs and prevented the decrease in the number 
of ACSs on the GBM. En = Endothelial cell; Fp = foot process. Arrows indicate ACSs. Bar = 1    m.   d   The 
number of ACSs on the GBM. ACSs on the GBM stained with polyethyleneimine were evaluated by count-
ing the number of dense deposits along the GBM and expressed as the number per 1,000 nm length of the 
GBM. Columns show the mean values and bars the standard errors. White column: unilaterally nephrec-
tomized control rats (n = 3); black column: nephritic rats (n = 4); gray column: rats treated with compound 
A (n = 4).   *  p   !   0.05: significantly different from the control group.   #  p   !   0.05: significantly different from 
the nephritis group. 143
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  Discussion 
  In this study, we investigated the action of a novel MMP inhibitor, compound A, in 
chronic anti-Thy1.1 nephritis. There are previous reports that investigated the action of 
MMP inhibitors using anti-Thy1.1 nephritis. BB-1101, a non-selective MMP inhibitor, has 
been shown to induce a decrease in ECM deposition with improvement in massive protein-
uria   [24]  . SI-27, a broad-spectrum inhibitor applied by subcutaneous implantation, signifi-
cantly reduced glomerular cell number and suppressed collagen deposition   [30]  . However, 
these studies were based on acute nephritic models, with an interest in the accumulation of 
ECM and glomerular cell proliferation. In our previous study, we have shown that enhanced 
MMP-2 activity contributes to glomerular injury by altering the GBM component in chron-
ic nephritic rats. This prompted us to study the effect of an MMP inhibitor on the damage 
of the GBM and GECs in an irreversible glomerulonephritic model.
  GBM plays a central role in the control of the filtration function and the retention of the 
glomerular structure. The permeability of the GBM is defined as both size- and charge-se-
lective properties. GECs cover the outer aspect of the GBM with extending foot processes 
  Fig. 6.   Immunostaining for desmin. Unilaterally nephrectomized control rat (  a  ), nephritic rat (  b  ), and rat 
treated with compound A (  c  ). Arrows indicate desmin deposition (  b ).   d   Semiquantitative analysis of the 
degree of staining for glomerular desmin. Columns show the mean values and bars the standard errors. 
White column: unilaterally nephrectomized control rats (n = 3); black column: nephritic rats (n = 4); gray 
column: rats treated with compound A (n = 4).   *  p   !   0.05: significantly different from the control group. 
  #  p   !   0.05: significantly different from the nephritis group. 144
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and play a pivotal part in maintaining the stability of the glomerular tuft architecture and 
modulating GBM permeability. Therefore, damage of the GBM and GECs leads to an in-
crease in proteinuria. We have previously reported sustained proteinuria in chronic anti-
Thy1.1 nephritic rats, associated with a decreased number of ACSs on the GBM, an abnormal 
remodeling of type IV collagen in the GBM, and predominant injury in GECs   [16, 27]  . The 
present study demonstrates that the treatment with the MMP inhibitor compound A pre-
vented the loss of ACSs on the GBM. Furthermore, administration of compound A dimin-
ished abnormal fusion of foot processes and obviously prevented damage of GECs. These 
results show that the renoprotective effect of compound A on nephritis is associated with a 
relief of the deterioration in GBM constitution and function and conservation of GEC func-
tion. We have previously discussed that MMP-2 causes extensive structural remodeling dur-
ing glomerular injury due to its possible involvement in the disruption of the GBM   [16]  . An 
abnormal structure of the GBM may rupture the contact with GECs, leading to GEC disor-
der. GEC damage, induced by puromycin aminonucleoside, results in the development of 
proteinuria with a decreased number of ACSs on the GBM   [31]  . Therefore, aberrant changes 
in GBM components and GECs evoked by the persistent activation of MMP-2 may be a piv-
otal part in the progression of chronic Thy1.1 nephritis.
  Glomerulosclerosis and tubulointerstitial fibrosis are common features in end-stage kid-
ney failure. In the process of kidney fibrosis, the balance between matrix synthesis and deg-
radation shifts to favor accumulation of ECM  [2] . Myofibroblasts identified by the expression 
of     -smooth muscle actin contribute to the progression of both human and experimental 
nephropathy   [32–37]  . In sustained glomerular and tubulointerstitial scarring, MCs and 
TECs undergo phenotype changes and acquire myofibroblast properties, characterized by 
the increased production of interstitial matrix  [38, 39] . The presence of myofibroblasts in the 
development of glomerular and tubulointerstitial fibrosis has been demonstrated in anti-
Thy1.1 nephritis  [23, 40] . It has been reported that MMP-2 contributes to the process of phe-
notype changes in MCs and TECs   [10, 11, 15]  . We have previously demonstrated that MMP-
2 activity is enhanced in anti-Thy1.1 nephritis  [16] . Compound A obviously suppressed ECM 
deposition with decreased gene expressions of TGF-    1 as well as    1(I),     1(III), and    1(IV) 
collagen in the renal cortex. Therefore, our finding suggests that increased activity of MMP-
2 partly contributed to the progression of chronic anti-Thy1.1 nephritis, eventually leading 
to glomerulosclerosis and tubulointerstitial fibrosis. Furthermore, it is assumed that com-
pound A might prevent phenotype changes in MCs and TECs to myofibroblasts by the inhi-
bition of MMP-2 action. It has recently been discussed that the disruption of tubular base-
ment membrane by MMP-2 induces the development of TEC phenotype changes, and selec-
tive MMP-2 inhibitors have a potential to treat CKD   [12]  .
  In conclusion, we have shown that the treatment with the synthetic MMP inhibitor com-
pound A exhibited an ameliorative effect in an irreversible glomerulonephritic model. Our 
results indicate that activation of MMP-2 plays an important role in the progression of 
chronic nephritis underlying ECM accumulation in the glomeruli and tubulointerstitial area 
and impairment of GBM integrity and GECs. These findings suggest that inhibition of 
MMP-2 could be a potent approach to intervention in progressive glomerulonephritis. This 
hypothesis should be tested further, for instance using MMP-2-deficient mice.
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